Effect of rimonabant on weight reduction and cardiovascular risk.
van Oosten
Bw
B
Killestein
J
J
Polman
Ch
Ch
D063387:Cannabinoid Receptor Antagonists; D006801:Humans; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000503:physiopathology; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects* / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D043882:Receptors, Cannabinoid / Q000502:physiology; D000077285:Rimonabant
D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D000077285:Rimonabant